Table 16.

—[Recommendations 5.1-5.3] Warfarin vs Aspirin in Patients With Systolic LV Dysfunction (Ischemic and Nonischemic)^97-99

Outcomes	Participants (Studies), Follow-up	Quality of the Evidence (GRADE)	Relative Effect (95% CI)	Anticipated Absolute Effects Over 5 y
				Risk With Aspirin	Risk Difference With Warfarin (95% CI)
Total mortality	1,358 (3 RCT), 23-27 mo	Low due to risk of biasa and imprecisionb	RR 0.95 (0.76-1.19)	193 per 1,000c	No significant difference; 10 fewer per 1,000 (from 46 fewer to 36 more)
MId	1,358 (3 RCT), 23-27 mo	Low due to risk of biasa and imprecisionb	RR 0.99 (0.35-2.84)	33 per 1,000c	No significant difference; 0 fewer per 1,000 (from 21 fewer to 60 more)
Strokee	1,358 (3 RCT), 23-27 mo	Low due to risk of biasa and imprecisionb	RR 0.34 (0.13-0.97)	24 per 1,000c	16 fewer per 1000 (from 21 fewer to 1 fewer)
Major extracranial bleedf	1,358 (3 RCT), 23-27 mo	Low due to risk of biasa and imprecisionb	RR 1.97 (0.89-4.3)	30 per 1,000c	No significant difference; 29 more per 1,000 (from 3 fewer to 99 more)
Burden of treatment	Not applicable	High	Warfarin > Aspirin	Warfarin: daily medication, dietary and activity restrictions, frequent blood testing/monitoring, increased hospital/clinic visits
				Aspirin: daily medication only

See Table 1-3 legends for expansion of abbreviations.

^aTwo of three trials were stopped early (one for benefit, one for slow enrollment); problems with blinding.

^bWide CIs include benefit and harm.

^cControl group risk estimates derived from event rates from aspirin arm of the pooled studies.

^dFatal and nonfatal MIs not reported separately in all studies.

^eFatal and nonfatal strokes not reported separately in all studies, types of strokes (ischemic/hemorrhagic) not reported.

^fDefinition of major hemorrhage varied.